Immix Biopharma Inc (IMMX) Stock Price, Quote & News

Company Profile

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was in...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 651 8041

Website: www.immixbio.com

Address:

11400 West Olympic Boulevard, Suite 200, Los Angeles, United States

Cultler Apr. 5 at 1:33 AM

$IMMX

0 · Reply

aWorkingMan Apr. 4 at 1:33 PM

$IMMX

0 · Reply

Jooner420 Apr. 4 at 1:33 AM

$IMMX

0 · Reply

EKingsler Apr. 3 at 1:33 PM

$IMMX

0 · Reply

LuckyInvested Apr. 3 at 1:33 AM

$IMMX

0 · Reply

OfficialStocktwitsUser Apr. 2 at 11:28 PM

$IMMX RSI: 42.41, MACD: 0.1185 Vol: 0.84, MA20: 9.45, MA50: 8.04 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Dingalingading Apr. 2 at 10:09 PM

$IMMX 🐴“Scalpers struttin’ around after that 8.40 flush like they did something. Please. I’ve seen stronger moves from a barn door in a windstorm. You boys had your little joyride, but by the time we closed at 8.93 you were right back in the stable where you belong. We closed with a stronger base than Tuesday, higher lows and a tighter range. Buyers trotting around like they own the place. Monday, bring a helmet — I’m galloping over your stop‑hunts.”

0 · Reply

osamabinrussell Apr. 2 at 9:18 PM

$IMMX CAR-T therapies already do $3B+ in annual sales while only being given at 5% of U.S. hospitals because of neurotoxicity. NXC-201 is designed to be dosed much more broadly. If that holds up, the TAM opens up significantly

0 · Reply

dudududucharles Apr. 2 at 9:12 PM

$IMMX 70% organ responses in evaluable patients and CRS lasting a median of just 1 day. The tolerability story here is genuinely differentiated vs. most CAR T programs

0 · Reply

Mungermind Apr. 2 at 6:29 PM

$IMMX IMMX cash burn for trial completion was about 5-10% of comparative cell therapy programs. It is remarkable. They have a fraction of the employees that are really only recently expanding as they approach commercialization. They have boot-strapped this thing from Day 1. They have never sold a share. They are true believers in the plan. At this stage in their product development, I do increasingly wish they would message more about expanded indications (primary ALA, MM, autoimmune). I did notice a clear difference in their posture and professionalism once Nancy Chang came aboard. I hope that the 13G funds and IB teams have a further impact. The risk-adjusted peak revenue projections from Morgan Stanley was about 800M and citizens was 1.2B Was this just with the R/R ALA market or did they assume the expanded indications?

2 · Reply

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Mar 3, 2026, 8:45 AM EST - 4 weeks ago

Immix Biopharma to Participate in Upcoming Investor Conferences

Jan 28, 2026, 8:45 AM EST - 2 months ago

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201

Dec 11, 2025, 12:10 AM EST - 4 months ago

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Dec 9, 2025, 5:45 PM EST - 4 months ago

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Dec 7, 2025, 6:20 PM EST - 4 months ago

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

$At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Dec 7, 2025, 6:15 PM EST - 4 months ago

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Nov 12, 2025, 8:45 AM EST - 5 months ago

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch

Nov 6, 2025, 2:39 PM EST - 5 months ago

Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'

Nov 3, 2025, 8:45 AM EST - 5 months ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025

Oct 14, 2025, 8:45 AM EDT - 6 months ago

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 6, 2025, 4:05 PM EDT - 6 months ago

Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Oct 1, 2025, 8:45 AM EDT - 6 months ago

Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference

$Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2$

Sep 18, 2025, 1:30 PM EDT - 7 months ago

Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Sep 11, 2025, 9:15 AM EDT - 7 months ago

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

Sep 8, 2025, 4:05 PM EDT - 7 months ago

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Aug 25, 2025, 9:30 AM EDT - 7 months ago

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Aug 6, 2025, 12:30 PM EDT - 8 months ago

Immix Biopharma Announces Other Serious Diseases Strategy

Jul 11, 2025, 9:36 AM EDT - 9 months ago

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

$Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis$

Jul 7, 2025, 9:35 AM EDT - 9 months ago

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

Jun 6, 2025, 9:39 AM EDT - 10 months ago

Immix Biopharma Attends FDA CEO Forum in Washington DC

$Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

Jun 3, 2025, 2:55 PM EDT - 10 months ago

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

May 23, 2025, 9:05 AM EDT - 11 months ago

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

$Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis$

May 22, 2025, 4:02 PM EDT - 11 months ago

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

$Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis$

May 21, 2025, 4:03 PM EDT - 11 months ago

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Apr 23, 2025, 10:04 AM EDT - 1 year ago

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

$Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis$

Feb 10, 2025, 9:35 AM EST - 1 year ago

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Jan 7, 2025, 9:34 AM EST - 1 year ago

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

$Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis$

Dec 19, 2024, 9:35 AM EST - 1 year ago

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

$Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis$

Dec 16, 2024, 9:48 AM EST - 1 year ago

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

$Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024$

Dec 10, 2024, 9:39 AM EST - 1 year ago

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Dec 9, 2024, 9:33 AM EST - 1 year ago

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

$Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients$

Nov 25, 2024, 9:32 AM EST - 1 year ago

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

Oct 2, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Sep 19, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

$Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

Aug 28, 2024, 9:32 AM EDT - 1 year ago

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Jul 25, 2024, 9:36 PM EDT - 1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Jul 8, 2024, 9:31 AM EDT - 1 year ago

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Jun 17, 2024, 9:35 AM EDT - 1 year ago

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

$Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation$

May 10, 2024, 9:35 AM EDT - 2 years ago

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

Apr 29, 2024, 9:39 AM EDT - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Apr 18, 2024, 9:32 AM EDT - 2 years ago

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Apr 15, 2024, 9:36 AM EDT - 2 years ago

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Mar 20, 2024, 9:46 AM EDT - 2 years ago

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Mar 5, 2024, 9:35 AM EST - 2 years ago

Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative

Feb 21, 2024, 9:31 AM EST - 2 years ago

Immix Biopharma 12 Month Review Progress Update

Feb 8, 2024, 4:45 PM EST - 2 years ago

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Feb 7, 2024, 9:37 AM EST - 2 years ago

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Feb 5, 2024, 10:30 PM EST - 2 years ago

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

Feb 5, 2024, 3:20 PM EST - 2 years ago

Immix Biopharma Announces Proposed Public Offering of Common Stock

Cultler Apr. 5 at 1:33 AM

$IMMX

0 · Reply

aWorkingMan Apr. 4 at 1:33 PM

$IMMX

0 · Reply

Jooner420 Apr. 4 at 1:33 AM

$IMMX

0 · Reply

EKingsler Apr. 3 at 1:33 PM

$IMMX

0 · Reply

LuckyInvested Apr. 3 at 1:33 AM

$IMMX

0 · Reply

OfficialStocktwitsUser Apr. 2 at 11:28 PM

0 · Reply

Dingalingading Apr. 2 at 10:09 PM

0 · Reply

osamabinrussell Apr. 2 at 9:18 PM

0 · Reply

dudududucharles Apr. 2 at 9:12 PM

$IMMX 70% organ responses in evaluable patients and CRS lasting a median of just 1 day. The tolerability story here is genuinely differentiated vs. most CAR T programs

0 · Reply

Mungermind Apr. 2 at 6:29 PM

2 · Reply

IndecisiveTrader Apr. 2 at 3:27 PM

$IMMX

0 · Reply

Dingalingading Apr. 2 at 3:11 PM

$IMMX Sitting right at the level where the day actually begins.

0 · Reply

PowerfulForm Apr. 2 at 2:51 PM

$IMMX it’s up on only 45000 shares. It’s a trap

0 · Reply

Nolder Apr. 2 at 1:33 PM

$IMMX

0 · Reply

TradeWhizkid1004 Apr. 2 at 1:33 AM

$IMMX

0 · Reply

Dingalingading Apr. 1 at 8:23 PM

Classic accumulation day for $IMMX. Early push to 9.60, engineered flush to reload, and now we’re stacking higher lows off the 8.60–8.70 shelf. Volume supports the idea that this is a base‑building session before the next leg. Watching 9.40 → 10.10 as the next resistance ladder.

0 · Reply

Ivorthedriver Apr. 1 at 2:19 PM

$IMMX Question for the class: Does anyone know why: "Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immix Biopharma in a research note on Thursday, January 22nd." Just wondering what their reasoning is; as I can't see ANY reason to be more conservative here than a "Hold" at most. Ivorthedriver P.S. And I'm not at all interested in what Onald Trump has to say on the subject...

1 · Reply

BronnyTheKing Apr. 1 at 1:33 PM

$IMMX

0 · Reply

DragonAlgo Apr. 1 at 1:29 PM

🐉 $IMMX CALL — DragonAlgo® Signal Contract: IMMX CALL Expiry: 2026-08-21 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $2.80 Stop: $2.02 TP1: $3.64 TP2: $4.76 TP3: $6.72 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

Dingalingading Apr. 1 at 1:29 PM

$IMMX

0 · Reply

Xan16 Apr. 1 at 2:40 AM

$IMMX Found an idiot

1 · Reply

Flarelords Apr. 1 at 1:33 AM

$IMMX

0 · Reply

Market Cap	473.51M
Revenue (ttm)	0.00
Net Income (ttm)	-29.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	418,100
Avg Vol	859,802
Day's Range	N/A - N/A
Shares Out	52.97M
Stochastic %K	59%
Beta	0.20
Analysts	Strong Sell
Price Target	$18.25